Charles O'Bryan-Tear
Plus aucun poste en cours
Fortune : 215 961 $ au 31/03/2024
Profil
Charles Gillies O'Bryan-Tear worked as a Medical Director at Bristol-Myers Squibb Pharmaceuticals Ltd., Director at Affibody AB, Interim Medical Director at Genzyme Therapeutics Ltd., Vice President-Research & Development at GlaxoSmithKline Biologicals NV, Chief Medical Officer at Algeta ASA, and Chief Medical Officer at Scancell Holdings Plc.
He holds a doctorate from the University of Cambridge and an MBA from Cranfield University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 120 373 ( 0,04% ) | 215 961 $ | 31/03/2024 |
Anciens postes connus de Charles O'Bryan-Tear
| Sociétés | Poste | Fin |
|---|---|---|
| CLARITY PHARMACEUTICALS LTD | Director/Board Member | 15/05/2023 |
| SCANCELL HOLDINGS PLC | Chief Tech/Sci/R&D Officer | - |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Corporate Officer/Principal | - |
| ALGETA ASA | Chief Tech/Sci/R&D Officer | - |
Formation de Charles O'Bryan-Tear
| University of Cambridge | Doctorate Degree |
| Cranfield University | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SCANCELL HOLDINGS PLC | Health Technology |
| CLARITY PHARMACEUTICALS LTD | Health Technology |
| Entreprise privées | 5 |
|---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Health Technology |
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Commercial Services |
GlaxoSmithKline Biologicals NV
 GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
